Literature DB >> 11331880

New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage.

A Petit1, F Bihel, C Alvès da Costa, O Pourquié, F Checler, J L Kraus.   

Abstract

We have designed new non-peptidic potential inhibitors of gamma-secretase and examined their ability to prevent production of amyloid-beta 40 (Abeta40) and Abeta42 by human cells expressing wild-type and Swedish-mutant beta-amyloid precursor protein (betaAPP). Here we identify three such agents that markedly reduce recovery of both Abeta40 and Abeta42 produced by both cell lines, and increase that of C99 and C83, the carboxy-terminal fragments of betaAPP that are derived from beta-and alpha-secretase, respectively. Furthermore, we show that these inhibitors do not affect endoproteolysis of endogenous or overexpressed presenilins. These inhibitors are totally unable to affect the mDeltaEnotch-1 cleavage that leads to generation of the Notch intracellular domain (NICD). These represent the first non-peptidic inhibitors that are able to prevent gamma-secretase cleavage of betaAPP without affecting processing of mDeltaEnotch-1 or endoproteolysis of presenilins. The distinction between these two proteolytic events, which are both prevented by disruption of presenilin genes, indicates that although they are intimately linked with betaAPP and Notch maturation, presenilins are probably involved in the control of maturation processes upstream of enzymes that cleave gamma-secretase and Notch.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331880     DOI: 10.1038/35074581

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  26 in total

1.  Notch receptor cleavage depends on but is not directly executed by presenilins.

Authors:  Yoshihito Taniguchi; Helena Karlström; Johan Lundkvist; Tomohiko Mizutani; Akira Otaka; Monica Vestling; Alan Bernstein; Dorit Donoviel; Urban Lendahl; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

2.  A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish.

Authors:  Andrea Geling; Harald Steiner; Michael Willem; Laure Bally-Cuif; Christian Haass
Journal:  EMBO Rep       Date:  2002-07       Impact factor: 8.807

Review 3.  At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism.

Authors:  Taisuke Tomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-24       Impact factor: 3.000

Review 4.  Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.

Authors:  P C Wong; H Cai; D R Borchelt; D L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 5.  Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.

Authors:  D Schenk; D Games; P Seubert
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 6.  Implication of APP secretases in notch signaling.

Authors:  D Hartmann; J Tournoy; P Saftig; W Annaert; B De Strooper
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

7.  Presenilin 1 and Presenilin 2 Target γ-Secretase Complexes to Distinct Cellular Compartments.

Authors:  Xavier Meckler; Frédéric Checler
Journal:  J Biol Chem       Date:  2016-04-08       Impact factor: 5.157

8.  Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity.

Authors:  Huifang Ma; Sylvain Lesné; Linda Kotilinek; Jill V Steidl-Nichols; Mathew Sherman; Linda Younkin; Steven Younkin; Colleen Forster; Nicolas Sergeant; André Delacourte; Robert Vassar; Martin Citron; Paulo Kofuji; Linda M Boland; Karen H Ashe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 9.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

10.  Current experimental therapy for Alzheimer's disease.

Authors:  Sheng Chen; Xiao-Jie Zhang; Liang Li; Wei-Dong Le
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.